Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

New Kidney Disease Treatment Discovered by Nash Pharma

Stockhouse Editorial
0 Comments| January 14, 2019

Nash Pharmaceuticals, a wholly-owned subsidiary of Breathtec Biomedical Inc. (CSE: BTHOTCQB: BTHCDForum), announced on Monday that two new lead compounds for the possible new treatment of chronic kidney disease were discovered through pre-clinical product testing.

For more on this discovery and further results recently reported, click here.

The Company recently made news when Kulwant Malhi acquried an aggregate of 6,851,171 common shares of Breathtec, representing roughly 23.8% of the Company’s issued and outstanding shares.

FULL DISCLOSURE: Breathtec Biomedical Inc. is a client of Stockhouse Publishing.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.